Maria Jure-Kunkel

5PUBLICATIONS
74CO-AUTHORS
Molecular targetsAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 17, 2026
Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity.

|May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

|Oct 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem

|Feb 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.

Alexander Muik, Elena Garralda, Isil Altintas

|Jul 07, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.

Nabendu Pore, Song Wu, Nathan Standifer

Pageof 1

Frequent Collaborators

2 joint publications

Brandon W Higgs

2 joint publications

Elena Garralda

2 joint publications

Emiliano Calvo

2 joint publications

Panagiota Reiter